Upperton Pharma Solutions is proud to announce a significant leap forward in our commitment to excellence in pharmaceutical manufacturing. With a substantial investment of £1.2 million, we have recently installed the state-of-the-art Gerteis Mini-Pactor® roller compactor at our Trent Gateway facility.
Following the commission and build of Trent Gateway, a new 50,000sq ft gmp manufacturing facility in 2023, this £1.2 million investment underscores our dedication to staying at the forefront of pharmaceutical technology. The Gerteis Mini-Pactor®, renowned for its precision, reliability, and ability to produce high-quality granules with consistent particle size distribution, aligns seamlessly with our mission to deliver solutions to help our clients from feasibility to market.
Increased Capacity
The Gerteis Mini-Pactor® holds immense significance for Upperton Pharma Solutions as it positions us to increase our capacity, enhancing our dry granulation and scale-up capabilities.
Paul Kelsall, Director of Clinical Manufacturing at Upperton Pharma Solutions says: “Our long standing relationship with Gerteis has ensured the successful installation and training of the Gerteis roller compactor with our teams. I’m delighted to bring this technology into our facility, enabling us to increase our capacity and support more clients.”
Installation and Training
The installation of the Gerteis Mini-Pactor® was a meticulously planned process, involving collaboration with Gerteis experts to ensure seamless integration into our new facility infrastructure.
Gerteis technicians, equipped with specialised tools and expertise, oversaw the installation process, working with our manufacturing team to ensure the optimal placement of the roller compactor, integration with our existing equipment, and connection to power and utilities.
Through the installation, our operators and maintenance staff received comprehensive training covering set-up, machine operation, maintenance procedures, safety protocols, and troubleshooting techniques.
After installation, rigorous testing procedures were conducted including calibration of the machine, checking for alignment, and verifying its performance according to preset parameters.
Matt Chillman, Principal Scientist at Upperton said: “The Gerteis installation and training has been a huge success. Our team members have embraced this training and thoroughly enjoyed learning about the machine of this status. The knowledge provided by Gerteis team has been outstanding.”
Continued Investment
This investment is part of our ongoing dedication to continuous improvement and staying at the forefront of pharmaceutical manufacturing.
Ian Lafferty, Chief Technical Officer at Upperton Pharma Solutions adds: “We’re delighted to add the Gertis Mini Pactor® to our suite of technology at Upperton. Being able to offer its speed and capacity to our existing and new customers showcases our commitment to providing excellent customer service.”
Benefits of the Gerteis Mini-Pactor®
The Gerteis Mini-Pactor® roller compactor is set to significantly enhance our processes. With its cutting-edge technology, this compactor offers enhanced densification of dry blended powders, making it an ideal solution for handling active pharmaceutical ingredients (APIs) with poor flow properties and moisture sensitivity. The result is an improvement in product quality and consistency, aligning perfectly with our commitment to delivering excellence.
Upperton Pharma Solutions is excited about the future possibilities that the Gerteis Mini-Pactor® brings to our processes. This investment underscores our commitment to innovation, quality, and meeting the dynamic needs of the pharmaceutical market.
Want to learn more?
Are you looking to work with an innovative CDMO? Contact our team to learn more about how we can support you.
